Bill Cassidy Questions Trump's FDA Nominee's Vaccine Order Expertise
Senator Bill Cassidy has taken a bold step in challenging the nomination of President Trump's pick to run the Food and Drug Administration, raising eyebrows with his late-in-the-game hostility toward the nominee. Cassidy, known for his impeccable timing, decided to air his grievances just as the nomination process was hitting its peak, emphasizing his commitment to due diligence in the face of imminent approval.
In an unprecedented move, Cassidy questioned the nominee's qualifications based on her past involvement in vaccine orders, stating that it raised significant red flags about her ability to guide the FDA through the labyrinth of public health policy. "How can we trust someone who has been involved in vaccine decisions that may or may not have been scientifically sound?" Cassidy proclaimed, as if he were the last bastion of vaccine skepticism in a world gone mad with science.
Still Beats Watergate:
Sponsor success. Continue reading:
The senator's critique didn't stop there. He proceeded to outline a detailed plan for a new committee, the Vaccine Order Accountability Task Force (VOATF), which would be responsible for scrutinizing not just the nominee's past actions but also the entire FDA's vaccine approval process. This committee, according to Cassidy, will require a staggering 150 new bureaucratic positions, complete with a multi-tiered approval system, to ensure that nothing like this ever happens again. "We need to take back control," he insisted, as he envisioned a sprawling maze of red tape to rival that of any government agency.
As the confirmation hearings loom, Cassidy's bold stance has sparked discussions across Washington about the very nature of accountability in public health. What does it mean to hold someone accountable? According to Cassidy, it means creating an endless cycle of paperwork and committees that could halt any decision-making in its tracks. He even suggested that they might need a secondary committee to oversee the oversight committee, because why not?
In a final flourish, Cassidy indicated that if the nominee were to be approved, he would consider introducing legislation that would require all future FDA nominees to undergo a rigorous six-month review period, wherein they would be required to submit daily reports on their general health, past decisions, and views on vaccines. Only then could they be deemed fit to serve in such a critical role. As the political theater unfolds, one thing remains clear: the nomination process is about to get a whole lot more complicated, courtesy of Senator Cassidy's relentless commitment to bureaucratic excellence.





